Your browser doesn't support javascript.
loading
Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study.
Deng, Ya-Ya; Jiang, Ding-Yi; Zhu, Peng-Fei; Lu, Hongrui; Liu, Qian; Zhang, Xinyue; Pan, Shuang-Yue; Chen, Zhe-Ling; Yang, Liu.
Afiliación
  • Deng YY; Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, 310014, China.
  • Jiang DY; The Qingdao University Medical College, Qingdao, Shandong Province, 260075, China.
  • Zhu PF; Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, 310014, China.
  • Lu H; The Qingdao University Medical College, Qingdao, Shandong Province, 260075, China.
  • Liu Q; The Qingdao University Medical College, Qingdao, Shandong Province, 260075, China.
  • Zhang X; Graduate School of Clinical Medicine, Bengbu Medical College, Bengbu, 233000, Anhui Province, China.
  • Pan SY; The Qingdao University Medical College, Qingdao, Shandong Province, 260075, China.
  • Chen ZL; Graduate School of Clinical Medicine, Bengbu Medical College, Bengbu, 233000, Anhui Province, China.
  • Yang L; The Qingdao University Medical College, Qingdao, Shandong Province, 260075, China.
World J Surg Oncol ; 21(1): 129, 2023 Apr 11.
Article en En | MEDLINE | ID: mdl-37041581
BACKGROUND: Recently, many studies have shown that the progress of conversion therapy can provide surgical opportunities for patients with advanced gastric cancer (GC) and bring survival benefits. However, the results of the current study show that the regimen used in conversion therapy is still controversial. Apatinib, as the standard third-line treatment for GC, has an inconclusive status in conversion therapy. METHODS: This study retrospectively analyzed GC patients admitted to Zhejiang Provincial People's Hospital from June 2016 to November 2019. All patients were pathologically diagnosed, had unresectable factors, and received SOX regimen with or without apatinib as conversion therapy. RESULTS: A total of 50 patients were enrolled in the study. Altogether 33 patients (66%) received conversion surgery and 17 patients (34%) received conversion therapy without surgery. The median progression-free survival (PFS) between surgery group and non-surgery group were 21.0 versus 4.0 months (p < 0.0001), and the median overall survival (OS) were 29.0 versus 14.0 months (p < 0.0001). In conversion surgery group, 16 patients (16/33) were treated with SOX plus apatinib, and the R0 resection rate was 81.3%; 17 patients (17/33) were treated with SOX regimen along, and the R0 resection rate was 41.2% (p = 0.032). The PFS in the SOX combined with apatinib group was significantly longer than that of SOX group (25.5 versus 16 months, p = 0.045), and the median OS were 34.0 versus 23.0 months (p = 0.048). The addition of apatinib did not increase the incidence of serious adverse reactions throughout the preoperative therapy period. CONCLUSIONS: Patients with advanced inoperable gastric cancer could benefit probably from conversion chemotherapy and subsequence conversion surgery. Apatinib-targeted therapy combined with SOX chemotherapy may be a safe and feasible option for conversion therapy.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Antineoplásicos Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: World J Surg Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Antineoplásicos Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: World J Surg Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido